header image

R&D Recombinant Protein Research

The R&D Recombinant Protein Research unit focuses on developing human cell line-based recombinant biopharmaceuticals.

 

The unit has developed extensive experience in recombinant protein research and development, for example in blood clotting factors and growth factors expressed by a human embryonic kidney (HEK) 293F cell line.

 

High-Throughput Screening Technology (HTS) for optimised human cell clone selection has achieved a significant increase in efficiency and productivity of human cell clones expressing the desired recombinant protein product. Appropriate treatment of individual cell clones is ensured by our experienced staff using sophisticated technology tools in fermentation, purification and analytics.

 

Octapharma Biopharmaceuticals GmbH currently has several human cell-line derived recombinant products at different stages in the research pipeline.

 

Octapharma’s R&D Recombinant Proteins Research unit is based at Octapharma Biopharmaceuticals GmbH, a subsidiary of the Octapharma Group founded in 1997.

 

Octapharma Biopharmaceuticals GmbH is situated in the Neuenheimer Feld in Heidelberg, where the Octapharma Group has invested €25 million for the construction of a new scientific building complex. The new premises are in the vicinity of the Heidelberg Technology Park, close to scientific institutes such as the Ruprecht-Karls-University, the European Molecular Biology Laboratory (EMBL) and the German Cancer Research Center.